Multiple Myeloma

Multiple Myeloma

Outcomes for patients with multiple myeloma treated at Taussig Cancer Institute compare favorably with other reported outcomes. Life expectancy has not significantly changed since 2007, but there are too few patients in long-term follow-up for the cohort of patients who may derive benefit from recently approved drugs. Overall favorable data may reflect care by a specialized healthcare team, common use of maintenance therapy in myeloma, and access to novel therapies, including within the context of clinical trials. Cleveland Clinic is also one of two sites in the United States selected to trial AMG 424, an anti-CD38/CD3 bispecific T cell-recruiting antibody for relapsed and refractory multiple myeloma.

Five-Year Overall Survival of Patients With Multiple Myeloma After Start of Treatment (N = 1161)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
2009-2014 (N = 619)541463397325236
2015-2019 (N = 542)415263152611

ᵃNational comparison represents relative survival after diagnosis from Fast Stats: An interactive tool for access to Surveillance, Epidemiology, and End Results (SEER) cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed June 10, 2020.

Based on SEER 18 data, patients with multiple myeloma diagnosed between 2010 and 2016 had a 5-year relative survival rate of 53.9% from time of diagnosis, meaning death from other causes is not counted in this number, whereas it is counted in our analysis.

Five-Year Overall Survival of Patients With Multiple Myeloma by Age at Start of Treatment (N = 1161)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
2009-2014, < 75 (N = 507)457393341289205
2009-2014, ≥ 75 (N = 112)8470563631
2015-2019, < 75 (N = 441)341218129531
2015-2019, ≥ 75 (N = 101)74452380

The improvement of outcomes for myeloma in recent years is still limited to patients < 75 years of age at the start of therapy who had 5-year survival estimates of around 60% compared to around 40% for patients age 75 or older at the start of myeloma therapy. Although these data are not adjusted for age-related life expectancy, lack of improvement in relative survival has been reported for this age group.¹

References

¹Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997-2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014 Aug;15(9):931-42.